Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

This is a Phase 1 study testing a new cell therapy called GCC2005 — designed to target a protein called CD5 on cancer cells — for people with relapsed or treatment-resistant NK-cell or T-cell blood cancers that have not responded to two or more prior lines of chemotherapy. **You may be eligible if...** - You have been diagnosed with a CD5-positive NK-cell or T-cell blood cancer - Your cancer has relapsed or stopped responding after at least two prior standard chemotherapy regimens - There are no other available treatment options in your doctor's assessment - You have at least one measurable tumor - You have a good performance status (ECOG 0–2) **You may NOT be eligible if...** - Your cancer does not express the CD5 protein - You have significant organ dysfunction - You have active infections or autoimmune conditions - You have fewer than two prior lines of chemotherapy Talk to your doctor to see if this trial is right for you.